

## CLAIMS

1. (currently amended) An oral pharmaceutical dosage form comprising, in combination, a core, and a coating surrounding the core wherein the core comprises a resinate of an opiate, and

whereby the pharmaceutical oral dosage form further comprises an aversive agent and is not subject to abuse.

2. (previously presented) The oral pharmaceutical dosage form of claim 1 in which coating is an extended drug release coating.

3. (currently amended) An oral pharmaceutical dosage form of claim 2 in which the coating on the core ~~further~~ comprises the following components:

(a) from 1 to 85% by weight of a matrix polymer which is insoluble at a pH of from 1 to 7.5 and contributes to the control of the rate of release of the active ingredient in the stomach and intestines;

(b) from 1 to 30% of an enteric polymer which is substantially insoluble at a pH of from 1 to 4, sufficient to delay the release of the active ingredient in the stomach, but which is soluble at a pH of from 6 to 7.5 so as not to substantially delay release in the intestines,

(c) from 1 to 60% of a compound soluble at a pH of from 1 to 4, sufficient to enable initiation of release of the active ingredient in the stomach; the percentages being by weight based on the total weight of components (a), (b), and (c); the ratio of the components (a), (b), and (c) in the extended drug release coating being such that a dose of the pellet composition delivers to the patient a therapeutically effective amount of the active ingredient over the course of the predetermined interval, so as to maintain an active ingredient blood level at steady state of at least 75% of maximum blood level for more than approximately 4 hours and so that the time at which the active ingredient reaches its maximum concentration is between about 4 and about 30 hours.

4. (previously presented) The oral pharmaceutical dosage form of claim 1 in which the opiate is selected from the group consisting of codeine, dextromoramide, hydrocodone, hydromorphone, pethidine, methadone, morphine, oxycodone, difydrocodeine, fentanyl, and propoxyphene.

5. (previously presented) The oral pharmaceutical dosage form of claim 3 wherein the coating further comprises: as component (a), ethyl cellulose, a quaternary ammonium acrylic or methacrylic polymer, an acrylic or a methacrylic ester copolymer or a mixture thereof, as component (b), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, methacrylic acid:acrylic acid ester copolymer, hydroxypropyl methylcellulose acetate succinate, shellac, cellulose acetate trimellitate and mixtures thereof, and as component (c), polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol having a molecular weight of from 1700 to 20,000, polyvinyl alcohol and monomers therefor and mixtures thereof.

6. (previously presented) The oral pharmaceutical dosage form of claim 5 wherein the coating comprises: 35 to 75% by weight of component (a); 2-20% by weight of component (b); and 15-40% by weight of component (c).

7. (previously presented) The oral pharmaceutical dosage form of claim 6 wherein the coating comprises up to 50% of plasticizer selected from diethyl phthalate, triethyl citrate, triethyl acetyl citrate, triethyl acetin, tributyl citrate, polyethylene glycol having a molecular weight of from 200 to less than 1700 or glycerol and up to 75% of a filler selected from silicon dioxide, titanium dioxide, talc, alumina, starch, kaolin, polacrilin potassium, powdered cellulose and microcrystalline cellulose and, mixtures thereof, the percentages being based on the total weight of the coating.

8. (previously presented) The oral pharmaceutical dosage form of claim 7 wherein the coating contains component (a) 35 to 70%; component (b) 4 to 20%; component (c) 15 to 35%; and, plasticizer 4 to 30%.

9. (canceled)

10. (canceled)